Nathan A Koonce1, Charles M Quick2, Matthew E Hardee1, Azemat Jamshidi-Parsian1, Judith A Dent1, Giulio F Paciotti3, Dmitry Nedosekin4, Ruud P M Dings1, Robert J Griffin5. 1. Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas. 2. Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas. 3. CytImmune Sciences, Rockville, Maryland. 4. Department of Otolaryngology, University of Arkansas for Medical Sciences, Little Rock, Arkansas. 5. Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas. Electronic address: RJGriffin@uams.edu.
Abstract
PURPOSE: Although remarkable preclinical antitumor effects have been shown for tumor necrosis factor-α (TNF) alone and combined with radiation, its clinical use has been hindered by systemic dose-limiting toxicities. We investigated the physiological and antitumor effects of radiation therapy combined with the novel nanomedicine CYT-6091, a 27-nm average-diameter polyethylene glycol-TNF-coated gold nanoparticle, which recently passed through phase 1 trials. METHODS AND MATERIALS: The physiologic and antitumor effects of single and fractionated radiation combined with CYT-6091 were studied in the murine 4T1 breast carcinoma and SCCVII head and neck tumor squamous cell carcinoma models. RESULTS: In the 4T1 murine breast tumor model, we observed a significant reduction in the tumor interstitial fluid pressure (IFP) 24 hours after CYT-6091 alone and combined with a radiation dose of 12 Gy (P<.05 vs control). In contrast, radiation alone (12 Gy) had a negligible effect on the IFP. In the SCCVII head and neck tumor model, the baseline IFP was not markedly elevated, and little additional change occurred in the IFP after single-dose radiation or combined therapy (P>.05 vs control) despite extensive vascular damage observed. The IFP reduction in the 4T1 model was also associated with marked vascular damage and extravasation of red blood cells into the tumor interstitium. A sustained reduction in tumor cell density was observed in the combined therapy group compared with all other groups (P<.05). Finally, we observed a more than twofold delay in tumor growth when CYT-6091 was combined with a single 20-Gy radiation dose-notably, irrespective of the treatment sequence. Moreover, when hypofractionated radiation (12 Gy × 3) was applied with CYT-6091 treatment, a more than five-fold growth delay was observed in the combined treatment group of both tumor models and determined to be synergistic. CONCLUSIONS: Our results have demonstrated that TNF-labeled gold nanoparticles combined with single or fractionated high-dose radiation therapy is effective in reducing IFP and tumor growth and shows promise for clinical translation.
PURPOSE: Although remarkable preclinical antitumor effects have been shown for tumor necrosis factor-α (TNF) alone and combined with radiation, its clinical use has been hindered by systemic dose-limiting toxicities. We investigated the physiological and antitumor effects of radiation therapy combined with the novel nanomedicine CYT-6091, a 27-nm average-diameter polyethylene glycol-TNF-coated gold nanoparticle, which recently passed through phase 1 trials. METHODS AND MATERIALS: The physiologic and antitumor effects of single and fractionated radiation combined with CYT-6091 were studied in the murine 4T1 breast carcinoma and SCCVII head and neck tumor squamous cell carcinoma models. RESULTS: In the 4T1 murinebreast tumor model, we observed a significant reduction in the tumor interstitial fluid pressure (IFP) 24 hours after CYT-6091 alone and combined with a radiation dose of 12 Gy (P<.05 vs control). In contrast, radiation alone (12 Gy) had a negligible effect on the IFP. In the SCCVII head and neck tumor model, the baseline IFP was not markedly elevated, and little additional change occurred in the IFP after single-dose radiation or combined therapy (P>.05 vs control) despite extensive vascular damage observed. The IFP reduction in the 4T1 model was also associated with marked vascular damage and extravasation of red blood cells into the tumor interstitium. A sustained reduction in tumor cell density was observed in the combined therapy group compared with all other groups (P<.05). Finally, we observed a more than twofold delay in tumor growth when CYT-6091 was combined with a single 20-Gy radiation dose-notably, irrespective of the treatment sequence. Moreover, when hypofractionated radiation (12 Gy × 3) was applied with CYT-6091 treatment, a more than five-fold growth delay was observed in the combined treatment group of both tumor models and determined to be synergistic. CONCLUSIONS: Our results have demonstrated that TNF-labeled gold nanoparticles combined with single or fractionated high-dose radiation therapy is effective in reducing IFP and tumor growth and shows promise for clinical translation.
Authors: David G Kirsch; Max Diehn; Aparna H Kesarwala; Amit Maity; Meredith A Morgan; Julie K Schwarz; Robert Bristow; Sandra Demaria; Iris Eke; Robert J Griffin; Daphne Haas-Kogan; Geoff S Higgins; Alec C Kimmelman; Randall J Kimple; Isabelle M Lombaert; Li Ma; Brian Marples; Frank Pajonk; Catherine C Park; Dörthe Schaue; Phuoc T Tran; Eric J Bernhard Journal: J Natl Cancer Inst Date: 2018-04-01 Impact factor: 13.506
Authors: Nathan A Koonce; Mazen A Juratli; Chengzhong Cai; Mustafa Sarimollaoglu; Yulian A Menyaev; Judith Dent; Charles M Quick; Ruud P M Dings; Dmitry Nedosekin; Vladimir Zharov; Robert J Griffin Journal: Biochem Biophys Res Commun Date: 2017-08-16 Impact factor: 3.575
Authors: Gunnar Boysen; Azemat Jamshidi-Parsian; Mary A Davis; Eric R Siegel; Christine M Simecka; Rajshekhar A Kore; Ruud P M Dings; Robert J Griffin Journal: Int J Radiat Biol Date: 2019-01-15 Impact factor: 2.694
Authors: Samir V Jenkins; Dmitry A Nedosekin; Emily K Miller; Vladimir P Zharov; Ruud P M Dings; Jingyi Chen; Robert J Griffin Journal: Int J Hyperthermia Date: 2017-05-09 Impact factor: 3.914
Authors: Giulio F Paciotti; Jielu Zhao; Shugeng Cao; Peggy J Brodie; Lawrence Tamarkin; Marja Huhta; Lonnie D Myer; Jay Friedman; David G I Kingston Journal: Bioconjug Chem Date: 2016-10-18 Impact factor: 4.774
Authors: Naris Nilubol; ZiQiang Yuan; Giulio F Paciotti; Lawrence Tamarkin; Carmen Sanchez; Kelli Gaskins; Esther M Freedman; Shugeng Cao; Jielu Zhao; David G I Kingston; Steven K Libutti; Electron Kebebew Journal: J Natl Cancer Inst Date: 2018-09-01 Impact factor: 13.506